Hazardous Drug Compounding USP 800: The 2024 NIOSH List Update and What Every Facility Must Do Now

Introduction: A Regulatory Shift That Cannot Wait

More than 8 million U.S. healthcare workers are potentially exposed to hazardous drugs every year, according to CDC and NIOSH data. The documented risks are not abstract: carcinogenicity, teratogenicity, reproductive toxicity, organ damage, and genotoxicity all rank among the consequences of unprotected exposure. For the pharmacists, technicians, nurses, and clinical staff who handle these drugs daily, the stakes could not be higher.

USP General Chapter <800> became fully enforceable on November 1, 2023, ending years of delays that traced back to appeals filed in 2019. Compliance is no longer a matter of best practice or future planning. It is a current, binding obligation.

In December 2024, NIOSH published a restructured List of Hazardous Drugs in Healthcare Settings that fundamentally changed how facilities must classify, handle, and document hazardous drug workflows. This article addresses two compliance traps that follow from that update: the immediate documentation and protocol changes triggered by the 2024 restructuring, and the widespread misapplication of “antineoplastic” requirements to drugs that fall outside NIOSH Table 1.

Nationwide Compounding Rx® operates as a USP <800>-compliant facility that tracks these regulatory changes closely and maintains hazardous drug compounding at the leading edge of industry standards.

What Is USP <800> and Who Must Comply

USP General Chapter <800> is the U.S. Pharmacopeia standard governing the safe handling of hazardous drugs across all healthcare settings, not just compounding pharmacies. Its scope is deliberately broad. The chapter applies to every healthcare worker who receives, prepares, administers, transports, or otherwise comes into contact with hazardous drugs, including pharmacists, pharmacy technicians, nurses, and other clinical personnel.

That reach extends to every environment where hazardous drugs are handled: hospitals, outpatient oncology clinics, physician offices, and compounding pharmacies alike.

Enforcement comes from several directions. State Boards of Pharmacy cite <800> during routine inspections, and The Joint Commission cross-walks the standard into its accreditation reviews, inspecting for compliance with policies on staff training, garbing, PPE, engineering controls, and beyond-use dating. Violations can result in fines, license suspension, or revocation. While state adoption remains inconsistent and rule-making can take years, federal regulatory bodies and accreditors are actively enforcing compliance expectations.

The gaps are real. A July 2024 industry survey found that 89% of compounding facilities report meeting most or all requirements, but only 46% of hospitals report full compliance, still below the halfway mark.

The December 2024 NIOSH List: What Changed and Why It Matters

The 2024 NIOSH List of Hazardous Drugs in Healthcare Settings, published in the Federal Register on December 20, 2024, replaced the previous 2016 list. That eight-year gap left many facilities operating on outdated classifications.

The core structural change is significant. The list was restructured from three tables to two, eliminating Table 3, which had been reserved for drugs posing reproductive hazards only. Those Table 3 drugs were not dropped; they were redistributed into Table 2, meaning drugs once classified solely as reproductive hazards now carry the full Table 2 handling implications.

In total, 25 drugs were added to the 2024 list and 7 were removed.

This matters operationally because any drug newly added to the NIOSH list, or reclassified between tables, immediately triggers mandatory updates to a facility’s hazardous drug list, its Assessment of Risk documentation, its SOPs, its engineering control protocols, its PPE requirements, and its staff training records. Critically, there is no grace period. Organizations must update their compliance programs with no lead-in time following the list’s publication.

Understanding the New Two-Table Structure

Table 1: Antineoplastic Drugs. This is the highest-risk category, requiring the most stringent engineering controls, PPE, and handling protocols under USP <800>.

Table 2: Non-Antineoplastic Hazardous Drugs. This broader category now absorbs the former Table 3 reproductive hazard drugs. It covers agents that are hazardous for reasons other than antineoplastic activity, including organ toxicity, genotoxicity, and reproductive toxicity.

NIOSH classifies a drug as hazardous if it exhibits one or more of six criteria: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or a structure and toxicity profile that mimics existing hazardous drugs.

Eliminating Table 3 as a separate category does not reduce the hazard status of those drugs. It consolidates and, in many cases, elevates their handling requirements under Table 2. The two-table structure simplifies classification at the list level, but it increases the compliance burden for facilities that previously treated Table 3 drugs as a lower priority.

The Antineoplastic Compliance Trap: A Critical Distinction Most Facilities Are Getting Wrong

A common error is applying USP <800>’s most stringent “antineoplastic” requirements to every drug with antineoplastic properties, regardless of which NIOSH table it appears in.

The correct standard is precise. Per a 2020 USP revision bulletin and confirmed in the January 2026 USP FAQ document, the term “antineoplastic” in USP <800> refers specifically and exclusively to antineoplastic drugs listed in NIOSH Table 1.

In the 2024 list, some antineoplastic drugs appear in Table 2 rather than Table 1. USP <800>’s mandatory antineoplastic requirements, including specific C-PEC and C-SEC engineering control mandates, do not automatically apply to those Table 2 antineoplastics. Those drugs remain hazardous and must be handled according to USP <800> requirements for non-antineoplastic hazardous drugs, which may permit Assessment of Risk-based alternative containment strategies.

The danger runs both ways. Misapplying antineoplastic requirements to Table 2 drugs creates operational inefficiency, while failing to apply them to true Table 1 drugs is a direct compliance violation. Every facility should audit its current drug classifications against the 2024 NIOSH list and verify that antineoplastic designations align with Table 1 placement, not pharmacological category alone.

Immediate Action Required: Updating Your Assessment of Risk

The Assessment of Risk (AoR) is the formal, documented evaluation that allows facilities to determine appropriate alternative containment strategies for non-Table 1 hazardous drugs. It sits at the center of practical compliance yet is frequently misunderstood.

The AoR is not optional where alternative handling is desired. It must be conducted, documented, and maintained as part of the facility’s compliance records. A proper AoR must consider the drug’s physical form (liquid versus solid, tablet versus powder), the manipulation required (crushing, dissolving, compounding), the volume and frequency of handling, and the available engineering controls.

The 2024 NIOSH restructuring directly affects existing AoR documents. Any drug newly added to the list, reclassified between tables, or absorbed from the former Table 3 must be evaluated and incorporated into the facility’s AoR immediately. A thorough, current, and defensible AoR for Table 2 drugs may allow positive-pressure C-SEC environments or less restrictive engineering controls, but only if the documentation holds up during inspection.

The hazardous drug list itself must be reviewed at least every 12 months and updated whenever a new agent or dosage form is introduced.

Engineering Controls: Matching the Right Control to the Right Drug and Table

USP <800> relies on a two-tier framework: Containment Primary Engineering Controls (C-PECs) and Containment Secondary Engineering Controls (C-SECs).

Sterile HD compounding C-PEC: Must provide ISO Class 5 air quality, be externally vented, and consist of a Class II Biological Safety Cabinet (BSC) or Compounding Aseptic Containment Isolator (CACI), as OSHA guidance confirms.

Sterile HD compounding C-SEC: The buffer room must be ISO Class 7, maintain at least 30 air changes per hour (ACPH), and sustain negative pressure of 0.01 to 0.03 inches of water column relative to all adjacent areas, continuously, not just during active compounding.

Non-sterile HD compounding: C-PEC options include a Class I BSC, Containment Ventilated Enclosure (CVE), Class II BSC, or CACI. The C-SEC must maintain at least 12 ACPH and negative pressure, with surfaces that are smooth, impervious, and non-shedding.

The Containment Segregated Compounding Area (C-SCA) offers an alternative, but with a critical limitation: beyond-use dates (BUDs) for sterile preparations compounded in a C-SCA are capped at 12 hours, making it operationally impractical for most facilities with ongoing HD compounding needs.

For storage, refrigerated antineoplastic HDs must be kept in a dedicated refrigerator located in a negative-pressure area with at least 12 ACPH. Pass-through refrigerators cannot be used in negative-pressure rooms.

Facilities must verify that current C-PEC and C-SEC configurations remain appropriate for each drug’s table classification, particularly for drugs newly added or reclassified in 2024.

PPE Requirements: What the Standards Actually Require

Two pairs of chemotherapy gloves meeting the ASTM D6978 standard are required when compounding hazardous drugs. Single-gloving does not meet the standard.

For gowns, the ASTM F3267-22 standard for chemotherapy gowns is gaining wide acceptance as a best practice, and facilities should evaluate their current gown sourcing against it. Importantly, USP does not validate or certify PPE products for compliance. Facilities must determine appropriate PPE based on the specific handling activity and their own documented Assessment of Risk.

PPE requirements extend beyond compounding to all HD handling: receiving, transporting, administering, and waste disposal. Respiratory protection also matters; N95 respirators, with proper fit-testing, may be required for activities involving powder manipulation or aerosolization risk.

Any drug newly added or reclassified under the 2024 list requires a review of PPE protocols, with selections documented in updated SOPs and training records.

SOP and Training Record Updates: The Documentation Cascade

Standard Operating Procedures must be developed for every process involving hazardous drugs, including compounding, dispensing, spill management, and waste disposal, and reviewed at least annually.

The 2024 NIOSH list triggers a documentation cascade: updated hazardous drug list, then updated AoR, then updated SOPs, then updated training records. Each step must be completed and documented.

Spill control deserves particular attention. Qualified personnel and spill kits must be available at all times in all areas where HDs are routinely handled, a requirement frequently omitted from facility SOPs. All personnel who handle HDs must receive initial training and ongoing competency assessments, with records reflecting the current NIOSH list. Those obligations extend beyond pharmacy staff to nurses, physicians, and any other personnel who handle HDs, a gap frequently identified in hospital settings.

Facilities should document the date of every SOP and training update to demonstrate a timely response to the December 2024 publication, creating a defensible compliance timeline.

The Designated Person: The Role Facilities Most Often Get Wrong

The Designated Person (DP) is the qualified, trained individual responsible for developing and implementing procedures, overseeing compliance, ensuring personnel competency, and maintaining environmental controls. Failing to formally name and document a DP is one of the most frequently cited deficiencies during compounding pharmacy inspections.

Several misconceptions persist. The DP role is not limited to pharmacists. In large health systems, responsibilities can be distributed across multiple qualified individuals. The role must also be formally assigned and documented, never simply assumed.

The DP is the central accountability point for keeping the hazardous drug list, AoR, SOPs, and training records current, which makes this person responsible for all 2024 NIOSH list update actions. Because USP <795>, <797>, and <800> each require a designated person, facilities must ensure their DP documentation covers every applicable chapter. Designation should be recorded in writing, with a defined scope of responsibilities and confirmation that the DP has received training on the 2024 changes.

Environmental Monitoring: The Ongoing Compliance Obligation

Environmental wipe sampling for HD surface residue must be performed initially as a baseline benchmark and at least every six months thereafter to verify containment effectiveness. USP <800> does not prescribe absolute acceptable thresholds for HD residues, so detectable contamination typically triggers a root cause investigation and corrective action documentation.

Pressure differential monitoring is equally important. Negative pressure in C-SECs must be continuously maintained at 0.01 to 0.03 inches of water column and documented, not just verified during active compounding. Continuous automated monitoring systems offer real-time alerts and ongoing documentation, providing significant advantages over manual logging during inspections.

ACPH documentation must be maintained and available, demonstrating that the required rates (30 ACPH for sterile, 12 ACPH for non-sterile C-SECs) are consistently achieved. Facilities that add new hazardous drugs based on the 2024 list should conduct fresh baseline wipe sampling in affected areas.

Medical Surveillance: The Requirement Many Facilities Overlook

Medical surveillance is a required component of the exposure control program under USP <800>, not an optional best practice. Healthcare workers who handle hazardous drugs as a regular part of their job must be enrolled in a medical surveillance program.

A compliant program includes a baseline assessment at hire or role assignment, ongoing periodic assessments during employment, and an exit assessment when the worker leaves the HD-handling role. Assessments should include reproductive history, relevant lab testing, and documentation of any symptoms potentially related to HD exposure.

This is a frequently overlooked gap, especially in hospital and outpatient settings where HD handling is distributed across departments without centralized oversight. Facilities should audit surveillance enrollment against the roster of personnel who handle HDs, including anyone newly handling drugs added in 2024.

Special Considerations: Outpatient Oncology and Non-Pharmacy Settings

Outpatient oncology practices and physician offices face a unique challenge. Many handle hazardous drugs but are not licensed under state Boards of Pharmacy, creating a regulatory gray area. These settings remain subject to USP <800> but may not face the same inspection frequency as licensed pharmacies.

That does not mean they escape scrutiny. The Joint Commission’s accreditation standards reference USP <800> and will inspect for compliance with policies on staff training, garbing, PPE, engineering controls, and documentation, regardless of pharmacy licensure. The 2024 NIOSH list applies equally in these settings. Any facility that handles a listed drug must update its protocols. These practices should proactively assess their workflows and engage pharmacy compliance expertise to close identified gaps. Outsourcing to a compliant compounding pharmacy is one strategy these settings increasingly use to manage hazardous drug handling obligations.

How the 2023 USP <795> and <797> Revisions Connect to <800> Compliance

The November 2023 revisions to USP <795> (non-sterile compounding) and <797> (sterile compounding) were published alongside <800>’s enforcement date, creating an integrated compliance framework.

The revised chapters clarify facility design, engineering controls, documentation, and personnel practices that directly influence hazardous drug workflows. They also reduced historical interpretation gaps in cleanroom construction and certification, areas where facilities once had latitude that bred inconsistency. Any facility undergoing cleanroom upgrades or new construction must satisfy all three chapters simultaneously. A thorough compliance review should examine cleanroom design, certification records, and engineering control documentation against the updated <795> and <797> standards.

Nationwide Compounding Rx: Hazardous Drug Compounding You Can Trust

Regulatory guidance is only as valuable as the partner who applies it. Nationwide Compounding Rx® operates as a USP <800>-compliant compounding pharmacy committed to the highest standards of hazardous drug handling.

The facility maintains PCAB accreditation, held since the company’s early days, providing third-party validation of safety and quality that goes beyond minimum regulatory requirements. Its team brings a combined 40 years of pharmaceutical compounding experience, supported by an investment in modern, high-tech compounding technologies that reinforce rigorous handling protocols.

Nationwide Compounding Rx® sources all chemicals exclusively from FDA-inspected and cleared vendors, protecting the integrity of every preparation from raw material to finished product. Staying current with regulatory changes, including the 2024 NIOSH restructuring, is a core component of the pharmacy’s patient safety and quality-first philosophy. With nationwide reach across 47 states plus Washington, D.C., and a 1 to 2 business day turnaround, the pharmacy offers healthcare providers a reliable, compliant compounding partner.

Conclusion: The 2024 NIOSH List Is Not a Future Concern, It Is a Current Obligation

The December 2024 NIOSH restructuring, from three tables to two with 25 drugs added and Table 3 eliminated, is an immediate compliance obligation with no grace period.

Every facility must address five action areas now: (1) update the hazardous drug list against the 2024 NIOSH list; (2) revise the Assessment of Risk for affected drugs; (3) update SOPs for compounding, dispensing, spill management, and waste disposal; (4) retrain all HD-handling personnel and update training records; and (5) verify that engineering controls and PPE protocols align with the new table classifications.

The antineoplastic distinction bears repeating: USP <800>’s antineoplastic requirements apply only to NIOSH Table 1 drugs, not to all pharmacologically antineoplastic agents. Compliance is a continuous process, not a one-time certification. It requires ongoing environmental monitoring, medical surveillance, annual SOP review, and vigilance for future updates. Facilities that invest in rigorous, current compliance programs protect their patients, their staff, and their operational licenses.

Ready to Work With a USP <800>-Compliant Compounding Partner?

Healthcare providers and medical practices seeking a dependable hazardous drug compounding partner are invited to contact Nationwide Compounding Rx®. The pharmacy’s USP <800>-compliant facility, PCAB accreditation, and experienced team deliver the highest standards of hazardous drug handling.

Reach out today:

• Phone: 480-499-8379
• Toll-Free: 1-833-650-9836
• Website: www.NationwideCompounding.com
• Location: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260

With nationwide shipping to 47 states plus Washington, D.C., and a 1 to 2 business day turnaround, Nationwide Compounding Rx® combines accessibility with reliability. Providers with questions about specific compounding needs, drug classifications, or USP <800> compliance considerations are encouraged to connect with the team for knowledgeable guidance and trusted partnership in the evolving landscape of hazardous drug compounding.